Inotiv Inc (NOTV)

$5.58

-0.37

(-6.22%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Inotiv Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 157.46M → 135.50M (in $), with an average decrease of 7.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 1.84M → -19.32M (in $), with an average decrease of 362.6% per quarter

  • Vs IDXX

    In the last 1 year, Idexx Laboratories, Inc. has given 23.1% return, outperforming this stock by 45.5%

Performance

  • $5.11
    $5.90
    $5.58
    downward going graph

    8.42%

    Downside

    Day's Volatility :13.39%

    Upside

    5.42%

    downward going graph
  • $1.61
    $8.07
    $5.58
    downward going graph

    71.15%

    Downside

    52 Weeks Volatility :80.05%

    Upside

    30.86%

    downward going graph

Returns

PeriodInotiv IncSector (Health Care)Index (Russel 2000)
3 Months
127.76%
12.8%
0.0%
6 Months
70.12%
10.8%
0.0%
1 Year
-27.34%
15.1%
-6.4%
3 Years
-67.12%
30.2%
-19.6%

Highlights

Market Capitalization
142.1M
Book Value
$9.86
Earnings Per Share (EPS)
-1.29
Wall Street Target Price
15.5
Profit Margin
-5.67%
Operating Margin TTM
-6.1%
Return On Assets TTM
0.4%
Return On Equity TTM
-12.66%
Revenue TTM
585.2M
Revenue Per Share TTM
22.79
Quarterly Revenue Growth YOY
10.4%
Gross Profit TTM
157.2M
EBITDA
60.9M
Diluted Eps TTM
-1.29
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.15
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.85
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Inotiv Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 177.78%

Current $5.58
Target $15.50

Company Financials

FY18Y/Y Change
Revenue
26.3M
↑ 8.68%
Net Income
-194.0K
↓ 121.95%
Net Profit Margin
-0.74%
↓ 4.39%
FY19Y/Y Change
Revenue
43.6M
↑ 65.55%
Net Income
-790.0K
↑ 307.22%
Net Profit Margin
-1.81%
↓ 1.07%
FY20Y/Y Change
Revenue
60.5M
↑ 38.64%
Net Income
-4.7M
↑ 493.04%
Net Profit Margin
-7.75%
↓ 5.94%
FY21Y/Y Change
Revenue
89.6M
↑ 48.18%
Net Income
10.9M
↓ 332.55%
Net Profit Margin
12.16%
↑ 19.91%
FY22Y/Y Change
Revenue
547.7M
↑ 511.19%
Net Income
-337.3M
↓ 3195.57%
Net Profit Margin
-61.58%
↓ 73.74%
FY23Y/Y Change
Revenue
572.4M
↑ 4.52%
Net Income
-105.1M
↓ 68.83%
Net Profit Margin
-18.37%
↑ 43.21%
Q3 FY22Q/Q Change
Revenue
150.5M
↓ 12.86%
Net Income
-244.2M
↑ 6766.03%
Net Profit Margin
-162.27%
↓ 160.21%
Q4 FY22Q/Q Change
Revenue
150.5M
↑ 0.0%
Net Income
-243.6M
↓ 0.22%
Net Profit Margin
-161.92%
↑ 0.35%
Q1 FY23Q/Q Change
Revenue
151.5M
↑ 0.66%
Net Income
-9.6M
↓ 96.05%
Net Profit Margin
-6.36%
↑ 155.56%
Q2 FY23Q/Q Change
Revenue
157.5M
↑ 3.96%
Net Income
1.8M
↓ 119.11%
Net Profit Margin
1.17%
↑ 7.53%
Q3 FY23Q/Q Change
Revenue
140.7M
↓ 10.62%
Net Income
-9.7M
↓ 625.16%
Net Profit Margin
-6.87%
↓ 8.04%
Q4 FY23Q/Q Change
Revenue
135.5M
↓ 3.72%
Net Income
-19.3M
↑ 99.96%
Net Profit Margin
-14.26%
↓ 7.39%
FY18Y/Y Change
Total Assets
31.3M
↑ 53.15%
Total Liabilities
20.4M
↑ 70.58%
FY19Y/Y Change
Total Assets
42.0M
↑ 34.26%
Total Liabilities
31.3M
↑ 53.4%
FY20Y/Y Change
Total Assets
61.6M
↑ 46.72%
Total Liabilities
54.0M
↑ 72.68%
FY21Y/Y Change
Total Assets
321.9M
↑ 422.55%
Total Liabilities
216.7M
↑ 301.37%
FY22Y/Y Change
Total Assets
962.9M
↑ 199.17%
Total Liabilities
603.1M
↑ 178.29%
FY23Y/Y Change
Total Assets
856.5M
↓ 11.05%
Total Liabilities
588.0M
↓ 2.5%
Q3 FY22Q/Q Change
Total Assets
962.9M
↓ 17.54%
Total Liabilities
603.1M
↑ 8.84%
Q4 FY22Q/Q Change
Total Assets
962.9M
↑ 0.0%
Total Liabilities
603.1M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
868.7M
↓ 9.79%
Total Liabilities
596.0M
↓ 1.18%
Q2 FY23Q/Q Change
Total Assets
854.8M
↓ 1.59%
Total Liabilities
579.5M
↓ 2.77%
Q3 FY23Q/Q Change
Total Assets
856.5M
↑ 0.2%
Total Liabilities
588.0M
↑ 1.47%
Q4 FY23Q/Q Change
Total Assets
835.5M
↓ 2.45%
Total Liabilities
581.3M
↓ 1.14%
FY18Y/Y Change
Operating Cash Flow
3.5M
↑ 182.12%
Investing Cash Flow
-8.1M
↑ 2281.71%
Financing Cash Flow
4.9M
↓ 680.21%
FY19Y/Y Change
Operating Cash Flow
1.8M
↓ 49.04%
Investing Cash Flow
-8.1M
↑ 0.93%
Financing Cash Flow
6.2M
↑ 25.96%
FY20Y/Y Change
Operating Cash Flow
1.3M
↓ 27.41%
Investing Cash Flow
-10.1M
↑ 24.32%
Financing Cash Flow
9.6M
↑ 55.37%
FY21Y/Y Change
Operating Cash Flow
10.7M
↑ 733.02%
Investing Cash Flow
-54.1M
↑ 433.61%
Financing Cash Flow
198.8M
↑ 1962.36%
FY22Y/Y Change
Operating Cash Flow
-5.2M
↓ 148.55%
Investing Cash Flow
-333.7M
↑ 517.32%
Financing Cash Flow
203.2M
↑ 2.17%
Q3 FY22Q/Q Change
Operating Cash Flow
171.0K
↓ 101.82%
Investing Cash Flow
-15.6M
↑ 7.51%
Financing Cash Flow
14.0M
↓ 1121.84%
Q4 FY22Q/Q Change
Operating Cash Flow
171.0K
↑ 0.0%
Investing Cash Flow
-15.6M
↑ 0.0%
Financing Cash Flow
14.0M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
12.8M
↑ 7406.43%
Investing Cash Flow
-8.4M
↓ 46.1%
Financing Cash Flow
-1.2M
↓ 108.29%
Q2 FY23Q/Q Change
Operating Cash Flow
3.7M
↓ 71.22%
Investing Cash Flow
-4.5M
↓ 46.56%
Financing Cash Flow
-1.0M
↓ 10.17%

Technicals Summary

Sell

Neutral

Buy

Inotiv Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inotiv Inc
Inotiv Inc
65.58%
70.12%
-27.34%
-67.12%
-67.12%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
10.31%
16.97%
23.09%
11.19%
174.29%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.66%
10.32%
-7.14%
8.13%
66.41%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
4.92%
4.27%
4.32%
25.08%
122.47%
Danaher Corp.
Danaher Corp.
11.63%
-0.66%
2.38%
15.77%
106.12%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
14.74%
12.9%
18.37%
28.41%
74.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inotiv Inc
Inotiv Inc
NA
NA
NA
-1.15
-0.13
0.0
NA
9.86
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
56.85
56.85
5.45
11.14
0.81
0.23
NA
17.87
Agilent Technologies Inc.
Agilent Technologies Inc.
32.28
32.28
2.54
5.49
0.22
0.08
0.01
20.01
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.23
36.23
2.78
21.56
0.13
0.05
0.0
120.73
Danaher Corp.
Danaher Corp.
44.65
44.65
3.29
7.04
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.59
32.59
1.57
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inotiv Inc
Inotiv Inc
Buy
$142.1M
-67.12%
NA
-5.67%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$47.4B
174.29%
56.85
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.7B
66.41%
32.28
18.15%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$216.6B
122.47%
36.23
13.99%
Danaher Corp.
Danaher Corp.
Buy
$186.9B
106.12%
44.65
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$44.9B
74.41%
32.59
9.06%

Institutional Holdings

  • Balyasny Asset Management LLC

    4.64%
  • Vanguard Group Inc

    3.96%
  • Wasatch Advisors Inc.

    3.20%
  • Millennium Management LLC

    1.53%
  • BlackRock Inc

    0.84%
  • Geode Capital Management, LLC

    0.72%

Corporate Announcements

  • Inotiv Inc Earnings

    Inotiv Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

*we are a cro and lab instrumentation provider* basi is a drug discovery and development services company with the energy and expertise to help you with your drug development project. we provide world-class research to the global pharmaceutical industry. our services include preclinical toxicology, early in vivo pk, bioanalysis and a full range of pharmaceutical analysis services. basi also manufactures innovative scientific instruments including the culex® automated in vivo sampling system which can collect blood, bile, microdialysates, activity behavior, telemetry data and more from awake, freely-moving subjects. we are known for our scientific expertise, responsiveness to clients, exemplary regulatory record, and helping our clients meet key milestones on time.

Organization
Inotiv Inc
Employees
1955
CEO
Mr. Robert W. Leasure Jr.
Industry
Healthcare

FAQs